Sugi Predict

Sugi Predict / Compounds / SCHEMBL4091306

SCHEMBL4091306

SCHEMBL4091306

CS(=O)(=O)c1cccc(NC(=O)NC(c2ccc(C(=O)Nc3nn[nH]n3)cc2)c2ccc(C3=CCCCC3)cc2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGAT2 Q10469 2/20 0.42
▸ LMNA P02545 2/20 0.40
▸ GCGR P47871 9/20 0.39
▸ ADCY6 O43306 1/20 0.39
▸ ADCY3 O60266 1/20 0.39
▸ ADCY9 O60503 1/20 0.39
▸ ADCY5 O95622 1/20 0.39
▸ ADCY8 P40145 1/20 0.39
▸ ADCY7 P51828 1/20 0.39
▸ ADCY2 Q08462 1/20 0.39
▸ ADCY1 Q08828 1/20 0.39
▸ ADCY4 Q8NFM4 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ GAA P10253 1/20 0.36
▸ CSF1R P07333 1/20 0.35
▸ GIPR P48546 2/20 0.35
▸ CA12 O43570 1/20 0.35
▸ CA1 P00915 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4087840 0.86 MGAT2 (0.45) MGAT2GCGRADCY6ADCY3ADCY9
SCHEMBL4096175 0.85 MGAT2 (0.40) MGAT2LMNAALDH1A1MEN1KMT2A
SCHEMBL4091978 0.84 GCGR (0.51) LMNAGCGRADCY6ADCY3ADCY9
SCHEMBL4082123 0.84 GCGR (0.47) MGAT2GCGRGIPR
SCHEMBL4097437 0.84 S1PR2 (0.40) MGAT2LMNAGCGRADCY6ADCY3
SCHEMBL4081625 0.84 ALDH1A1 (0.43) LMNAGCGRADCY6ADCY3ADCY9
SCHEMBL4091781 0.84 GCGR (0.43) MGAT2LMNAGCGRCSF1RGIPR
SCHEMBL4085175 0.83 GCGR (0.43) LMNAGCGRADCY6ADCY3ADCY9
SCHEMBL4091679 0.83 GCGR (0.52) MGAT2GCGRADCY6ADCY3ADCY9
SCHEMBL4085620 0.82 CYSLTR2 (0.42) LMNAGCGRADCY6ADCY3ADCY9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 — — EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 — — US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 — — US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 — — US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR MGAT2 149/4885LMNA 3643/4885GCGR 3/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR MGAT2 149/4885LMNA 3643/4885GCGR 3/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR MGAT2 149/4885LMNA 3643/4885GCGR 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.